Medpace (MEDP) reported Q3 earnings Monday of $3.01 per diluted share, up from $2.22 a year earlier.
Analysts polled by Capital IQ expected $2.78.
Revenue for the quarter ended Sept. 30 was $533.3 million, up from $492.5 million a year earlier.
Analysts surveyed by Capital IQ expected $541 million.
The company now expects 2024 revenue between $2.09 billion and $2.13 billion from previous guidance between $2.125 billion and $2.175 billion.
Analysts polled by Capital IQ expect $2.14 billion.
The company now expects diluted EPS between $11.71 and $12.09 from previous guidance between $11.24 and $11.93.
Analysts surveyed by Capital IQ expect $11.56.
The company's shares were falling past 10% in recent after-hours activity.
Price: 312.96, Change: -39.96, Percent Change: -11.32
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.